Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 1101 - 1150 of 1864 results
- Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles.
- Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice.
- Biologically active peptides interacting with the g protein-coupled formylpeptide receptor.
- Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
- In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
- Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
- Generation of a tumor-specific systemic response after intratumoral injection of IL-12 and IL-18-loaded polylactic acid microspheres.
- Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.
- Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.
- Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
- Transient activation of tumor-associated T-effector/memory cells promotes tumor eradication via NK-cell recruitment: minimal role for long-term T-cell immunity in cure of metastatic disease.
- Treatment with cetuximab in metastatic colorectal cancer patients who do not express the epidermal growth factor receptor.
- Phase I Evaluation of CDP791, a PEGylated Di-Fab' Conjugate that Binds Vascular Endothelial Growth Factor Receptor 2.
- First in Human Phase I Trial of 852A, a Novel Systemic Toll-like Receptor 7 Agonist, to Activate Innate Immune Responses in Patients with Advanced Cancer.
- CD8+ T Cells Induce Complete Regression of Advanced Ovarian Cancers by an Interleukin (IL)-2/IL-15 Dependent Mechanism.
- An oncolytic adenovirus redirected with a tumor-specific T-cell receptor.
- Human Papillomavirus 16/18 E7-Pulsed Dendritic Cell Vaccination in Stage IB-IIA Cervical Cancer Patients; A Phase I Escalating Dose Trial.
- Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.
- Macrophage migration inhibitory factor in cancer.
- Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.
- MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.
- Study of Immunotherapy of Murine Myeloma by an IL-21-Based Tumor Vaccine in BALB/C Mice.
- Oral administration of attenuated S.typhimurium carrying shRNA-expressing vectors as a cancer therapeutic.
- Multivalent 4-1BB binding aptamers costimulate CD8 T cells and inhibit tumor growth in mice.
- Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.
- Toxicological Protein Biomarker Analysis-An Investigative One-week Single Dose Intravenous Infusion Toxicity and Toxicokinetic Study in Cynomolgus Monkeys using an Antibody-cytotoxic Conjugate against Ovarian Cancer.
- CD200: A putative therapeutic target in cancer.
- Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines.
- Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
- Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases.
- CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells.
- Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer.
- Enhancement of antitumor activity of OK-432 (Picibanil) by Triton X-114 phase partitioning.
- Anti-tumor metastatic activity of beta-glucan purified from mutated Saccharomyces cerevisiae.
- Vaccination with in vitro grown whole tumor cells induces strong immune responses and retards tumor growth in a murine model of colorectal liver metastases.
- Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study.
- Sentinel lymph node as a target of molecular diagnosis of lymphatic micrometastasis and local immunoresponse to malignant cells.
- An epigenetic vaccine model active in the prevention and treatment of melanoma.
- Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer.
- Exponential Enhancement of Oncolytic Vesicular Stomatitis Virus Potency by Vector-mediated Suppression of Inflammatory Responses In Vivo.
- Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer.
- Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases.
- Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response.
- Controlled Internalization of Her-2/neu Receptors by Cross-linking for Targeted Delivery.
- 1E10 Anti-Idiotype Vaccine in Non-Small Cell Lung Cancer: Experience in Stage IIIb/IV Patients.
- Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease <1cm) associated with ovarian cancer or primary peritoneal carcinoma.
- Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting.
- Solamargine Enhances HER2 Expression and Increases the Susceptibility of Human Lung Cancer H661 and H69 Cells to Trastuzumab and Epirubicin.
- A phase 1 multi-dose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.
- Enhancement of T cell Activation by Immobilized hu5C8 (Anti-CD40L) Monoclonal Antibody.